People · Operator
Named in public records as an officer, director or promoter · active 2019–2022 · Medical Devices, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nanomedical Diagnostics, Inc. | — | Medical Devices | Series A | $12.0M | $38.0M | 2019 |
| Crisprqc Inc. | — | Biotechnology | Pre-Seed | $1.8M | $5.7M | 2022 |
Michael Heltzen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Heltzen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Grint | 2 | 5 |
| Ross Bundy | 2 | 2 |
| Nina Saberi | 1 | 5 |
| Biao He | 1 | 5 |
| Joseph Keegan | 1 | 4 |
| Tim Hoerr | 1 | 2 |
| Ross Helgren Bundy | 1 | 1 |
| Jonathan Kabakoff | 1 | 1 |
| Brett Goldsmith | 1 | 1 |
| George Bonaros | 1 | 1 |
| Kiana Aran | 1 | 1 |
| Toby Richardson | 1 | 1 |
| Chris Yoo | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.